改性精神类物质(仍在)临床试验中表现不佳
This week I want to look at where we are with psychedelics, the mind-altering substances that have somehow made the leap from counterculture to major focus of clinical research. Compounds like psilocybin—which is found in magic mushrooms—are being explored for all sorts of health applications, including treatments for depression, PTSD, addiction, and even obesity. Over…
来源文章
MIT Technology Review (United States) | 2026年3月20日
您的投票很重要
无需账号。您的投票会被保存并计入共识分析。 创建账号即可保存您的投票记录。
AI 翻译 · 显示原文
Psychedelics like psilocybin offer groundbreaking potential for treating mental health disorders, providing hope where traditional therapies have failed.
AI 翻译 · 显示原文
Relying on mind-altering substances for mental health treatment risks over-medication and neglecting holistic approaches like therapy and lifestyle changes.
AI 翻译 · 显示原文
Psychedelics could revolutionize addiction treatment, offering unique mechanisms that could help individuals break free from cycles of substance abuse.
AI 翻译 · 显示原文
The clinical trial results for psychedelics are mixed, indicating that while some patients benefit, many others do not, necessitating careful consideration before widespread use.
AI 翻译 · 显示原文
The hype around psychedelics in clinical trials may overshadow the need for rigorous scientific evaluation, potentially leading to premature acceptance in healthcare.
💡 使用说明
- • 添加陈述: 发布观点或问题(10 至 500 个字符)。
- • 投票: 对每条陈述选择同意、不同意或不确定。
- • 回应: 附上证据,详细阐述支持或反对的理由。
- • 共识: 参与人数足够后,分析会显示各意见群体及其共识所在。
Society Speaks 开放且独立。 您的支持让公民讨论远离广告和商业影响。
支持我们